Circulating irisin levels in newly diagnosed obstructive sleep apnea patients

Introduction: Obstructive sleep apnea syndrome (OSAS) is commonly associated with obesity, insulin resistance, metabolic syndrome, hypertension, and coronary artery disease. Irisin is a newly identified myokine and its serum concentration was found to be correlated with cardiac troponin and creatin kinase-MB in acute myocardial infarction patients. Furthermore, irisin levels were positively associated with endothelium-dependent vasodilation in type 2 diabetic patients.Aim: In this study, we aimed to investigate serum irisin level in the newly diagnosed OSAS patients.Materials and Methods: After obtaining ethical approval, 32 OSAS patients were included. All patients gave written informed consent. Diagnosis of OSAS was verified by an overnight polysomnography (PSG) and made by an apnea hypopnea index equal to or higher than 5. Venous blood samples were collected in the morning between 08.00 – 10.00 after PSG (n=25) or after one-night CPAP treatment (n=7). Serum irisin concentrations were studied by ELISA.Results and Conclusion: Serum irisin concentrations were significantly higher in newly diagnosed OSAS group than in OSAS group after one night of CPAP treatment (199.7±42.4 vs 159.7±18.3 ng/mL respectively; p<0.01). These results suggest that increased serum irisin levels can be reduced by CPAP treatment and elevated serum irisin levels may be due to increased respiratory muscle activity and body temperature.

Exenatide, a GLP-1 analog, has healing effects on LPS-induced autism model: Inflammation, oxidative stress, gliosis, cerebral GABA, and serotonin interactions

Erdogan, Mumin/0000-0003-0048-444XWOS: 000558438600001PubMed: 32745285Previous studies have established anti-inflammatory, antioxidant, and neuroprotective effects of Exenatide in the central nervous system. Since these mechanisms are thought to have important roles in the pathophysiology of autism, we hypothesized that Exenatide may have healing effects in autism. We tested this hypothesis by examining the effects of Exenatide in an experimental autism model created by lipopolysaccharide (LPS) exposure in the womb, with behavioral tests, histopathological examinations, and biochemical measurements. the autism model was created by administration of LPS (i.p) to pregnant rats on the 10th day of their pregnancy at a dose of 100 mu g/kg. on postnatal 21st day, a total of four groups were formed from offspring with regard to sex distribution and treatment. After a 45-day treatment, behavioral analysis tests were performed on rats. Subsequently, the rats were sacrificed and biochemical analysis [superoxide dismutase, tumor necrotizing factor alpha, nerve growth factor, 5-hydroxyindoleacetic acid, and glutamic acid decarboxylase-67] and histopathological analysis were performed. on the 10th day of the intrauterine period, LPS exposure was found to disrupt behavioral findings, increase inflammation and hippocampal gliosis, and decrease 5-HIAA, GAD-67, and NGF, especially in male rats. However, among the rats exposed to LPS in the intrauterine period, recipients of Exenatide demonstrated significant amelioration of findings. Exenatide therapy shows positive effects on behavioral disorders in an LPS-induced autism model. This agent probably exerts its effects by suppressing inflammation and oxidative stress and reducing hippocampal gliosis. in addition, Exenatide has also been shown to positively affect cerebral serotonergic and GABAergic effects

Spontaneous intracranial hypotension presenting with coma: a case report and literature review

Spontaneous intracranial hypotension is characterized by orthostatic headache in the absence of a history of head trauma or lumbar puncture, and diagnosis is confirmed by a specific cerebrospinal fluid pressure and neuroimaging findings. It rarely presents with coma. A 62-year-old man presented with progressive cognitive decline of 2 to 4 weeks' duration. He was diagnosed with spontaneous intracranial hypotension according to cerebrospinal fluid pressure and neuroimaging findings, and treated conservatively

Neuroprotective effects of octreotide on diabetic neuropathy in rats

WOS: 000402468200054PubMed ID: 28249248The purpose of the present study is to investigate the possible healing effects of octreotide (OCT) on motor performance, electrophysiological and histopathological findings of diabetic neuropathy in a rat model of diabetes mellitus (DM). To induce diabetes, rats were administered a single dose (60 mg/kg) of streptozotocin (STZ). Diabetic rats were treated either with saline (1 ml/kg/day, n = 7) or OCT (0.1 mg/kg/ day, n = 7) for four weeks. Seven rats served as control group and received no treatment. At the end of the study, electromyography (EMG), gross motor function (inclined plate test), general histology and the perineural thickness of sciatic nerve were evaluated. At the end of study, weight loss was significantly lower in OCT treated rats than that of saline treated ones (p < 0.001). Electrophysiologically, compound muscle action potential (CMAP) amplitudes of the saline treated DM group were significantly reduced than those of controls (p < 0.0001). Also, distal latency and CMAP durations were significantly prolonged in saline treated DM group (p < 0.05) compared to control. However, treatment of diabetic rats with OCT significantly counteracted these alterations in EMG. Furthermore, OCT significantly improved the motor performance scores in diabetic rats (p < 0.05). Histomorphometric assessment of the sciatic nerve demonstrated a significant reduction in perineural thickness in OCT treated group compared to saline group. In conclusion, OCT possesses beneficial effects against STZ-induced diabetic neuropathy, which promisingly support the use of OCT as a neuroprotective agent in patients with diabetic neuropathy. (C) 2017 Elsevier Masson SAS. All rights reserved